This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Click here for Great Britain and Northern Ireland Prescribing Information for MYLOTARG®▼ (gemtuzumab ozogamicin) and cytarabine.
Adverse event reporting information can be found at the bottom of the page.

MRD and Treatment Decisions video

Duration: 07:29

Speaker: Professor Adriano Venditti

In this video, Professor Venditti addresses the following questions:

1. What is Measurable Residual Disease (MRD) and why is it important?
2. What are the recommendations for MRD assessment in AML?
3. What is the relationship between MRD and prognosis in patients with AML?
4. What evidence is there to support the use of Gemtuzumab Ozogamicin (GO) in patients with 1st Line, de novo AML?
5. What evidence is there to support the use of GO in achieving MRD Negativity in patients with 1st Line, de novo AML?
6. Based on these data, what is your opinion of GO as a treatment option for patients with favourable- or intermediate-risk de novo AML?
​​​​​​​

​​​​Professor Adriano Venditti has been an Associate Professor in Haematology at the University of Rome Tor Vergata since 2001 and is now a UOSD director at the Polyclinic Tor Vergata Foundation. He graduated from the Sapienza University of Rome in 1986 with a degree in medicine and surgery, and went on to specialise in haematology, completing two UK fellowships - in the Department of Immunology at the Royal Free Hospital in London as a CNR scholarship winner, and later at the Department of Haematology and Cytogenetics at the Royal Marsden NHS Foundation Trust, London, UK. Prof. Venditti has been board-certified in haematology since 1989 and has authored over 200 publications in peer-reviewed journals.

Prof. Venditti’s main fields of interest include acute leukaemia, MDS, and chronic myeloproliferative disorders. He is the national coordinator of the AML1310 protocol for the treatment of adult patients aged <60 years with acute myeloid leukaemia. He is an elected member of the board of the Italian Society of Haematology and is a member of both the GIMEMA and EORTC acute leukaemia working parties.

Explore more

Download the fast facts PDF document to aid your understanding of MYLOTARG

Download the pdf

AML, Acute Myeloid Leukaemia; EORTC, European Organisation for Research and Treatment of Cancer; GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto (the Italian Adult Haematological Diseases Group); MRD, measurable residual disease; USOD, Unità operativa semplice dipartimentale (Simple departmental operating unit)


PP-MYL-GBR-0539. March 2022

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

Understand the evidence

Guidelines

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?